Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series scheduled for January 29, 2025, at 2:00 pm EST.
During the presentation, Robert Bitterman, CEO and Chairman of the Board, will showcase the company's proprietary INTASYL siRNA technology and provide updates on their ongoing clinical trial of PH-762 for treating skin cancers. The INTASYL technology is designed to enhance the effectiveness of immune cells in fighting cancer cells.
Stakeholders, investors, and interested parties are invited to attend this live virtual event. A replay will be available on the Renmark Financial Communications website. Participants are advised to use the latest version of Google Chrome for optimal connectivity.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PHIO declined 7.66%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm EST
Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present its proprietary INTASYL siRNA technology and an update on its on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio is committed to the pursuit of cancer free futures to improve the lives of patients by utilizing its Intasyl technology.
Phio's presentation and live Q&A will take place on Wednesday, January 29, 2025 at 2:00 pm EST.in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs
Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.
REGISTER HERE:
Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications
If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate cancer. INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells. INTASYL has also demonstrated enhancement adoptive cell therapy. Notably, INTASYL is a self-delivering RNAi technology focused on immuno-oncology therapeutics without the need for formulation enhancements or manipulations to reach its target.
Phio's lead clinical program, PH-762, is an INTASYL compound that silences PD-1. PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b trial (NCT# 06014086) received FDA clearance for an Investigational New Drug Application to evaluate PH-762 in the treatment of cutaneous SCC, melanoma and Merkel cell carcinoma in second quarter of 2023.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237992
FAQ
What will be discussed in Phio Pharmaceuticals' (PHIO) January 29, 2025 presentation?
How can investors attend Phio Pharmaceuticals' (PHIO) Virtual Non-Deal Roadshow on January 29, 2025?
What is the purpose of Phio Pharmaceuticals' (PHIO) INTASYL siRNA technology?
What is PH-762 and what is its current development status at Phio Pharmaceuticals (PHIO)?
Will there be a replay available of Phio Pharmaceuticals' (PHIO) January 29, 2025 presentation?
